Related Experiment Video

Updated: May 3, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Hypersensitivity to aurora kinase inhibitors in cells resistant against platinum- containing anticancer agents

Masaki Akiyama, Hiroto Izumi, Ke-Yong Wang

  • 1President Laboratory, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. k-kohno@med.uoeh-u.ac.jp.

Anti-Cancer Agents in Medicinal Chemistry
|February 14, 2014
PubMed

Insights

Aurora B kinase (AURKB) is overexpressed in platinum-resistant cancers. Inhibiting AURKB resensitizes cells to cisplatin and oxaliplatin, offering a potential therapeutic strategy to overcome chemotherapy resistance.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Aurora kinases are crucial for cell division and implicated in cancer development.
  • Targeting aurora kinases offers a promising avenue for molecular cancer therapy.

Purpose of the Study:

  • To investigate the role of aurora B kinase (AURKB) in cisplatin- and oxaliplatin-resistant cells.
  • To evaluate the efficacy of AURKB inhibition in overcoming platinum-based chemotherapy resistance.

Main Methods:

  • Assessed AURKB expression in resistant cell lines.
  • Examined the effect of AURKB downregulation on chemosensitivity.
  • Tested sensitivity to specific AURKB inhibitors (AZD1152 HQPA, ZM447439) in resistant cells.

Main Results:

  • AURKB was found to be overexpressed in both cisplatin- and oxaliplatin-resistant cells.
  • Downregulating AURKB restored sensitivity to cisplatin and oxaliplatin, but not other chemotherapeutics.
  • Resistant cells exhibited hypersensitivity to AURKB inhibitors, indicating an 'addiction' to AURKB.

Conclusions:

  • Overexpression of AURKB contributes to cisplatin and oxaliplatin resistance.
  • AURKB inhibitors show potential in overcoming platinum resistance.
  • Combining AURKB inhibitors with platinum-based chemotherapy may enhance treatment outcomes.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.4K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820